Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec, Harvard in Antibacterials Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Evotec, Harvard in Antibacterials Alliance

Will leverage chemical and biological expertise

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Evotec AG has entered a research collaboration with Harvard University to discover and develop novel anti-bacterial agents based on a validated target family in bacterial cell wall biosynthesis.
 
Harvard and Evotec will identify and optimize small molecule inhibitors of bacterial cell wall synthesis, based on enabling technologies and chemical starting points licensed from Harvard. Evotec will use its drug discovery infrastructure to address anti-bacterial targets, specifically peptidoglycan biosynthesis (PGB). Evotec will commercialize any resulting assets.
 
“We are pleased to have entered into this collaboration with Harvard in the antibacterial space,” said Dr. Werner Lanthaler, chief executive officer of Evotec. “The lack of new antibacterials has been broadly recognized as a major unmet medical need as antibiotics pipelines are drying up while resistance against existing drugs is on the rise. We are excited to team up with our colleagues at Harvard to systematically target a highly validated but under-exploited anti-bacterial target family.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics